Literature DB >> 8816587

Intraductal carcinoma associated with invasive carcinoma of the breast. A comparison of the two lesions with implications for intraductal carcinoma classification systems.

N S Goldstein1, T Murphy.   

Abstract

Intraductal carcinoma (DCIS) is a useful marker for predicting which women will develop a recurrent breast malignancy. The authors examined 150 consecutive, mammographically detected, T1 invasive carcinomas associated with DCIS to study the DCIS and compare it to its associated invasive carcinoma. Intraductal carcinoma nuclear grades were assigned to each duct on a scale of 1 to 3. The percentage of DCIS ducts that were involved by each grade was quantitated into quartiles for cases with more than one DCIS nuclear grade. The predominant architectural pattern corresponding to each DCIS nuclear grade was recorded. Ninety-two percent of the 150 invasive carcinomas were of ductal type, 4% were tubular, and the remainder were various other subtypes. Nine percent of the DCIS cases were nuclear grade 1. The remaining 91% of cases were almost evenly distributed between mixed DCIS nuclear grades 1 and 2 (19%), pure DCIS nuclear grade 2 (24%), mixed DCIS nuclear grade 2 to 3 (25%), and pure DCIS nuclear grade 3 (22%). Two percent of cases were a mixture of DCIS nuclear grades 1 and 3 or 1, 2, and 3. All pure DCIS nuclear grade 1 or mixed 1 and 2 were associated with well or moderately differentiated invasive carcinomas, whereas the majority (61%) of the pure DCIS nuclear grade 3 cases were associated with poorly differentiated invasive carcinomas. There was no relation between the DCIS architectural pattern and the invasive carcinoma grade. In general, the DCIS nuclear grade correlates with the grade of the invasive carcinoma. Unlike DCIS architecture, nuclear grade heterogeneity within DCIS associated with invasive carcinoma is minimal. DCIS classification systems based on nuclear grade have merit because there is little variation in nuclear grade within a given patient's lesion.

Entities:  

Mesh:

Year:  1996        PMID: 8816587     DOI: 10.1093/ajcp/106.3.312

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  7 in total

Review 1.  Electron microscopic findings for diagnosis of breast lesions.

Authors:  Shin-ichi Tsuchiya; Fu Li
Journal:  Med Mol Morphol       Date:  2005-12       Impact factor: 2.309

2.  Avoiding Pitfalls in the Statistical Analysis of Heterogeneous Tumors.

Authors:  David E Axelrod; Naomi Miller; Judith-Anne W Chapman
Journal:  Biomed Inform Insights       Date:  2009-01-01

3.  Heterogeneity Between Ducts of the Same Nuclear Grade Involved by Duct Carcinoma In Situ (DCIS) of the Breast.

Authors:  Naomi A Miller; Judith-Anne W Chapman; Jin Qian; William A Christens-Barry; Yuejiao Fu; Yan Yuan; H Lavina A Lickley; David E Axelrod
Journal:  Cancer Inform       Date:  2010-09-07

4.  Minimal breast cancer: evaluation of histology and biological marker expression.

Authors:  E A Dublin; R R Millis; P Smith; L G Bobrow
Journal:  Br J Cancer       Date:  1999-07       Impact factor: 7.640

5.  Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ.

Authors:  N Bijker; J L Peterse; L Duchateau; E C Robanus-Maandag; C A Bosch; C Duval; S Pilotti; M J van de Vijver
Journal:  Br J Cancer       Date:  2001-02       Impact factor: 7.640

6.  Effect of quantitative nuclear image features on recurrence of Ductal Carcinoma In Situ (DCIS) of the breast.

Authors:  David E Axelrod; Naomi A Miller; H Lavina Lickley; Jin Qian; William A Christens-Barry; Yan Yuan; Yuejiao Fu; Judith-Anne W Chapman
Journal:  Cancer Inform       Date:  2008-03-01

7.  Grade of recurrent in situ and invasive carcinoma following treatment of pure ductal carcinoma in situ of the breast.

Authors:  R R Millis; S E Pinder; K Ryder; R Howitt; S R Lakhani
Journal:  Br J Cancer       Date:  2004-04-19       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.